Last data update: Sep 16, 2024. (Total: 47680 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Khamis AU [original query] |
---|
Monovalent rotavirus vaccine effectiveness and impact on rotavirus hospitalizations in Zanzibar, Tanzania: data from the first 3 years post-introduction
Abeid KA , Jani B , Cortese MM , Kamugisha C , Mwenda JM , Pandu AS , Msaada KA , Mohamed AS , Khamis AU , Parashar UD , Saleh AA . J Infect Dis 2016 215 (2) 183-191 BACKGROUND: Low-income settings challenge the level of protection provided by live attenuated oral rotavirus vaccines. Rotarix (RV1) was introduced in the United Republic of Tanzania in early 2013, with two doses given at the WHO-recommended schedule of ages 6 and 10 weeks, along with oral polio vaccine. METHODS: We performed active surveillance for rotavirus hospitalizations at the largest hospital in Zanzibar, Tanzania from 2010-2015. Using case-test-negative control methodology, we estimated the vaccine effectiveness of 2 RV1 doses in preventing rotavirus hospitalizations. RESULTS: Based on 204 rotavirus cases and 601 test-negative controls aged 5-23 months, the effectiveness of 2 RV1 doses against hospitalization for rotavirus diarrhea was 57% (95% CI 14-78). Effectiveness tended to increase against hospitalizations with higher severity, reaching 69% (95% CI 15-88) against the top quarter of cases. Compared to pre-vaccine period, there was an estimated 40%, 46% and 69% reduction in the number of rotavirus hospitalizations among infants in 2013, 2014 and 2015, respectively, and a 36%, 26% and 64% reduction among children aged <5 years. CONCLUSIONS: With data encompassing three pre- and three post-introduction years, our results indicate that successful delivery of RV1 on the current WHO schedule can provide substantial health benefits in a resource-limited setting. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Sep 16, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure